Dublin: The White House has confirmed that President Donald Trump’s planned 100% tariff on pharmaceuticals will not apply to countries with existing trade agreements with the United States. Instead, a 15% tariff will be imposed on products from partners such as the European Union and Japan.
The clarification follows Trump’s announcement of sweeping tariffs on certain branded, patented pharmaceutical products without U.S.-based manufacturing plants, set to take effect October 1. While concerns remain over the new 15% levy, EU officials expressed relief that the feared 100% tariff will not be applied.
European Trade Commissioner Maroš Šefčovič met with U.S. Trade Commissioner Jamieson Greer in Washington this week to discuss the measures. U.S. trade spokesperson Olof Gill described the 15% tariff on EU exports as “insurance”, stressing that European producers would not face higher duties and that both sides remain committed to the joint trade statement. This includes extending tariff exemptions to additional sectors.
Gill also reiterated that Brussels and Washington had previously agreed to cap tariffs on pharmaceuticals, semiconductors, and timber at 15%. Earlier this week, tariffs on EU vehicle imports into the U.S. were reduced from 27.5% to 15%, and the European Commission is pursuing further carve-outs for industries such as beverages.
Relief for Ireland
The announcement comes as a particular relief for Ireland, one of the EU’s largest pharmaceutical exporters. Of the EU’s €120 billion worth of pharma exports last year, €33 billion originated from Ireland.
Foreign Minister Simon Harris welcomed the confirmation of the 15% tariff cap, noting that its potential impact would be carefully assessed in coordination with EU partners. Enterprise Ireland also described the clarification as reassuring. Jonathan McMillan, head of the agency’s Trade and Tariff Response Team, said it reinforced commitments made under the EU–US trade agreement reached in July.
Irish Samachar English News
Comments are closed.